June 26, 2018
DEA to hopefully change CBD scheduling within 90 days.
The US Food and Drug Administration announced Monday June 25, 2018 the approval of the first cannabis based prescription medication.
The medicine is called Epidiolex and is a plant-derived oral solution of cannabidiol (CBD). CBD is a chemical component of marijuana that does not cause intoxication or a euphoric high. The London based GW Pharmaceuticals plc, is expecting another significant decision where the US Drug Enforcement Administration (DEA) reclassifies CBD.
This could unlock the opportunity to other marijuana-derived medications as well as ease restrictions on other cannabis research.
Read the entire article here
